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334A ABSTRACTS- Myocardial Ischemia and Infarction 
There was no difference in the prevalence of thrombogenic disorders among the survi- 
vors of MI according to the presence of normal or diseased coronary arteries. 
Conclusions: there is a relatively high prevalence of hereditary thrombogenic disorders 
in pts who suffered a MI _<35 years, and this may contribute to the pathogenesis of MI in 
young pts. 
1193-45 Is Age Related to Platelet Activity in Patients Presenting 
With Acute Coronary Syndromes? 
Paul A. Gurbel, E. Magnus Ohman, Matthew T. Roe, Raymond D. Bahr, W. Brian Gibler, 
Victor L. Serebruany, for the EARLY Thai Investigators, Sinai Hosptial, Baltimore, 
Maryland, Duke University, Durham, North Carolina. 
BACKGROUND: Bleeding is a major risk of pharmacologic strategies to treat acute cor- 
onary syndromes (ACS) and is increased in the eldedy. This risk may be related to an 
age-dependent reduction in platalet activity.METHODS: Baseline platelet function and 
flow cytometry with menoclonal antibodies directed against multiple surface receptors 
were investigated in a substudy of the EARLY Trial (n=56) that treated patients present- 
ing to the Emergency Department with early or late (12-24 hours) eptifibatide.RESULTS: 
A significant negative correlation was observed between age and indicators of platelet 
activity. PAC-1 expression, a marker of Gp lib/Ilia activity, fell as age increased (r = - 
.5250) and platelet aggregation to 10H tool ADP was also lower in the elderly (r = -.5938, 
see figure). CONCLUSION: At presentation to the Emergency Department with acute 
coronary syndromes, older patients have less active platelets. The age-dependent 
increase in bleeding risk in the elderly may be related to reduced platelet activity as com- 
pared to younger patients. Monitodng of platelet function may lessen the bleeding risks in 
ACS treatment by appropriate adjustment of platelet inhibition. 
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1193-46 Sustained Reduction in Coagulation Activity During 
Long-Term Dalteparin Treatment in Unstable Coronary 
Artery Disease 
Jonas Oldaren. Edk Diderbolm, Eva Lindmark, Lars Wallentin, Agneta Siagbahn, Medical 
Sciences, Cardiology and Clin Chemist~ Uppsala, Sweden. 
Background: Short-term treatment with low molecular mass heparin is known to reduce 
coagulation activity. We have investigated the influence on markers of coagulation activ- 
ity by long-term treatment with dalteparin, a low molecular mass heparin, in patients with 
unstable coronary artery disease (CAD). 
Methods: Coagulation activity was monitored in 562 out of the 2267 patients with unsta- 
ble CAD in the Scandinavian multicenter study FRISC II. All patients were treated with 
subcutaneous dalteparin 120 IU/kg twice daily for 5-7 days and then randomised to pla- 
cebo (n=287) or long-term treatment with daltaparin (n=275) for 3 months. Women 
weighing < 80 kg, and men weighing < 70 kg, received daltaparin 5,000 IU twice daily 
and above these weight limits the daltaparin dose was 7,500 IU twice daily during long- 
term treatment. Prothrombin fragment 1+2 (F1+2) and D-dimer were analysed during in- 
hospital daltepadn treatment, during long-term daltaparin/placabo treatment at 6 weeks 
and 3 months, and at 6 months follow-up. Data are medians with Mann Whitney test. 
Results: See table 
Conclusion: There was a sustained reduction of coagulation activity, as indicated by 
lower levels of F1+2 and D-dimer, dudng long-term treatment with dalteparin as com- 
pared to placebo. A significantly higher coagulation activity was seen at follow-up 3 
months after termination of long-term daltaparin treatment, whereas coagulation activity 
was unchan~led at follow-up in the placebo group. 
F1+2, nmol/L D-dimer. microg/L 
daltepadn, 120 IU/kg p dalteparin, 120 IU/kg p 
In-hospital 0.79 0.78 0.8 30 31 0.5 
daltaparin placebo daltaparin placebo 
6 weeks 0.87 1.15 <0.001 20 43 <0.001 
3 months 0.86 1.10 <0.001 21 42 <0:001 
Post-treatment Post-treatment 
6 months 1.05 1.11 0.2 36 38 0.1 
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1193-47 Enhaoed Cort iso l  Secretion Does Not Control Aspirin- 
Insensitive Thromboxane Biosynthesis in Patients With 
Acute Coronary Syndromes 
Giulia Renda, Maria G. Sciulli, Francesca Seta, Stefania Tecconelli, Marta L. Capone, 
Antonio Rebuzzi, Paola Patrianani. "G. D'Annunzio" University of Chieti School of 
Medicine, Chieti, Italy, Catholic University School of Medicine, Rome,/ta/y 
We have explored 1) the involvement of monocyte COX-2 induction in enhanced throm- 
boxane (TX) A2 biosynthesis occurring episodically in patients with acute coronary syn- 
dromes treated with low-dose aspidn, and 2) the influence of endogenous cortisol 
secretion in TXA2 biosynthesis in this setting. Whole blood TXB2 and udnary 11-dehy- 
dro-TXB2 and cortisol levels were evaluated by RIA. In patients with acute myocardial 
infarction (AMI; n=15), unstable angina (UA; n=10) and chronic stable angina (CSA; 
n=15), the treatment with low-dose aspirin (160 mg/d) caused a similar suppression of 
platalet COX-1 activity while the biosynthesis of TXA2. in vivo, as reflected by the excre- 
tion of 11-dehydro-TXS2 in overnight udne samples, was significantly higher in patients 
with AMI and UA vs. SA [206±161 (p<O.01) and 126±86 (p<O.05) vs. 69±34 pg/mg crea- 
tinine, respectively]. The production of TXB2 in heparinized whole blood incubated for 4 h 
with bectedal endotoxin (LPS, 1 ~g/ml) was significantly (p<0.05) higher in patients with 
AMI vs. CSA but not vs. UA (52±29, 26.8±17 and 30±21 pg/lO 3 monocytes) and was pro- 
foundly suppressed (77-87%) by the selective COX-2 inhibitor L-745,337 (26 p.M). 
Plasma levels of C-reactive protein (CRP), a marker of systemic inflammation, were 
higher in patients with AMI and UA vs. those with CSA [40±43 (p<0.01) and 15±14 
(p<0.05) vs. 3.9±2.6 rag/I]. The urinary excretion of cortisol was significantly (p<0.01) 
higher in patients with AMI vs. those with UA and CSA [176±130, 58±57 and 46±52 ng/ 
mg creatinine]. Urinary cortisol correlated with 11-dehydro-TXB2 (r=0.516, n=36, 
p<0.01), LPS-induced TXB2 (r=0.552, n=20, p<0.05) and plasma CRP (r=0.408, n=36, 
p<0.05). Differently from patients with SA, in AMI and UA, the circadian rhythm of urinary 
cortisol excretion did not occur. In conclusion, COX-2 expression in circulating mono- 
cytes may participate in episodes of aspirin-insensitive TXA2 biosynthesis in acute coro- 
nary syndromes. Activation of the hypothalamic-pituitary-edrenal axis occurs in patients 
with acute coronary syndromes but it seems insufficient o control the inflammatory reac- 
tion presumably triggering aspirin-insensitive TXA2 biosynthesis in this setting. 
1193-48 Increased Homocysteine Levels Predict a More 
Complicated Course Following Acute Myocardial 
In farct ion 
Shlomi Matetzky. Dov Freimark, Sela Ben-Ami, Ilya Novikov, Michael Eldar, Hanoch Hod, 
Heart Institute Sheba Medical Center, Tel Hashomer, Israel 
Background: Although hyperhomocysteinema is associated with hypercoagulability and 
piatelet aggregation, and interferes with fibrinolysis, data are scarce regarding the effect 
of hyperhomocystaine levels on clinical outcome in patients with acute myocardial infarc- 
tion (AMI). 
Methods: Homocystaine was determined on admission in 160 consecutive patients with 
AMI by HPLC methodology with fluorescent detection. 
Results: Mean homocysteine levels in the entire group were 14±11 micromole/L. 
Homocysteine levels were higher in male (p<0.01) and non-diabetic patients (p<0.Ol), 
but were not associated with other risk factors or age (r=0.07, p=0.42). Patients (n=22) 
with homocysteine 320 micromole/L (34±9) compared with those of lower levels (n=135, 
10±4), had a lower incidence of diabetes mellitus (9% vs 28%, p=0.06). There was no 
significance difference regarding the in-hospital course and indices of infarct size, includ- 
ing peak CPK (p=0.7) and LVEF (p=0.45) in both groups of patients. Among the 112 
catheterized patients, those with homocysteine 320 and <20 micromol/L had a similar dis- 
tribution of the infarct-related artery, number of diseased coronary artedes (p=0.87) and 
prevalence of multi-vessel coronary artery disease (p=0.9). However, during mean fol- 
low-up of 30 months, the patients with higher homocysteine levels had a higher incidence 
of re-hospitalization for recurrent coronary events (38% vs 17%, p<0.O4) and a higher 
mortality rate (18% vs 5%, p<0.05). 
Conclusion: Elevated levels of homocystaine in AMI patients are associated with a higher 
incidence of recurrent coronary events and mortality. 
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1194-38 Pred ic tors  of  Emergency Coronary Artery Bypass 
Grafting in Percutaneous Coronary Interventions 
Niranjan Seshadri, Naveen Acharva. Penny Houghtaling, Eugene Blackstone, Stephen 
G. Ellis, Patrick L. Whitlow, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background and Aim: Advances in interventional cardiology have resulted in a 
decreased need for emergency coronary artery bypass grafting (EMCABG) following 
percutaneous coronary interventions (PCI). We sought to determine the current preva- 
lence and predictors of EMCABG. 
Methods: A retrospective review of all PCIs performed for a 4-year period between 1/2/ 
1997 and 12/29/2000 at our institution. Multivadable logistic regression modeling was 
performed to determine predictors of EMCABG. 
Results: There were 8830 PCI procedures performed (mean age 64± 12 yrs, 2575 F, 
